Myomo (MYO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Executive summary
Annual meeting scheduled for June 25, 2026, to be held virtually for stockholders of record as of April 29, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of two Class III directors, Paul R. Gudonis and Thomas F. Kirk, to serve until the 2029 annual meeting.
Advisory (non-binding) vote on executive compensation for named executive officers.
Ratification of CBIZ CPAS P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of Amendment No. 3 to the 2018 Stock Option and Incentive Plan, increasing shares by 1,833,000.
Approval of an amendment to the certificate of incorporation to increase authorized common stock to 100,000,000 shares.
Advisory shareholder proposal regarding the classification of directors, if properly presented.
Approval of adjournments or postponements to solicit additional proxies if needed.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals except for proposal 6, on which it makes no recommendation.
Latest events from Myomo
- Recurring revenue growth, payer expansion, and clinical validation drive path to profitability.MYO
Sidoti Micro-Cap Virtual Conference21 May 2026 - Wearable robotics drive growth with expanding reimbursement and recurring revenue focus.MYO
Investor presentation20 May 2026 - Recurring revenue and expanded payer coverage fuel growth and improved financial outlook.MYO
A.G.P.'s Annual Virtual Healthcare Conference20 May 2026 - Strong market position, expanding reimbursement, and recurring revenue drive robust growth.MYO
Corporate presentation14 May 2026 - Shareholders will vote on director elections, compensation, auditor, equity plan, and capital structure changes.MYO
Proxy filing14 May 2026 - Q1 revenue up 3% to $10.1M, gross margin 68.2%, recurring sources now 49% of revenue.MYO
Q1 202614 May 2026 - Shareholders will vote on key governance, compensation, and capital structure proposals at the annual meeting.MYO
Proxy filing4 May 2026 - Expanding reimbursement and clinical validation drive growth, targeting 158M covered lives by 2026.MYO
Investor presentation7 Apr 2026 - Full-year revenue up 26% to $40.9M, with 2026 guidance at $43–$46M and recurring growth focus.MYO
Q4 20259 Mar 2026